Related Experiment Video
Updated: May 17, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Models of excellence: improving oncology drug development
M R Sharma1, M L Maitland, M J Ratain
1Department of Medicine, University of Chicago, Illinois, USA.
Abstract:
Simulations based on disease-progression models and phase II trial results can predict phase III results and have the potential to improve oncology drug development by informing end-of-phase II decisions (EOP2Ds). Many barriers impede effective use of modeling and simulation (M&S) for EOP2Ds in oncology: concerns about model validity, lack of access to M&S results and patient-level data, limited awareness of M&S among academic oncologists, and inexperience fitting M&S into the drug development timeline.
Related Concept Videos
Drug Discovery: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
Clinical Trials: Overview
Preclinical Development: Overview
Pharmacodynamic Models: Overview
